Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one E.sub.h-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.

Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one E.sub.h-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.

Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one E.sub.h-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.

The use of chlorine dioxide (CLO2) to kill or disable pathogens such as viruses, particularly those of the Coronavirus family. A certain amount of CLO2 is used via different modalities, particularly through one's nose or mouth, as a therapeutic. CLO2 can treat, cure and/or prevent diseases, such as methicillin resistant Staphylococcus aureus (MRSA), fungal infections, the common cold, and more particularly a current disease in the year 2020, known as COVID-19. The invention will not only kill or disable SARS CoV-2, which causes COVID-19, but will also kill or disable the next Coronavirus, SARS CoV-3, once CoV-2 mutates and escapes any vaccine against it.

The use of chlorine dioxide (CLO2) to kill or disable pathogens such as viruses, particularly those of the Coronavirus family. A certain amount of CLO2 is used via different modalities, particularly through one's nose or mouth, as a therapeutic. CLO2 can treat, cure and/or prevent diseases, such as methicillin resistant Staphylococcus aureus (MRSA), fungal infections, the common cold, and more particularly a current disease in the year 2020, known as COVID-19. The invention will not only kill or disable SARS CoV-2, which causes COVID-19, but will also kill or disable the next Coronavirus, SARS CoV-3, once CoV-2 mutates and escapes any vaccine against it.

Colloidal antiseptic compositions for treating wounds and/or for use in surgical operations are provided. The compositions form an elastic air- and water-permeable biodegradable film on the wound surface and have antiseptic, hemostatic, anti-inflammatory, wound-healing, and especially anesthetic and antitoxic effects. The compositions include a collagen hydrolysate, one or more salts of alginic acid and one or more antiseptics, and additionally include unithiol and dimethylsulfoxide. The compositions may also optionally include one or more anesthetics.

Colloidal antiseptic compositions for treating wounds and/or for use in surgical operations are provided. The compositions form an elastic air- and water-permeable biodegradable film on the wound surface and have antiseptic, hemostatic, anti-inflammatory, wound-healing, and especially anesthetic and antitoxic effects. The compositions include a collagen hydrolysate, one or more salts of alginic acid and one or more antiseptics, and additionally include unithiol and dimethylsulfoxide. The compositions may also optionally include one or more anesthetics.

The invention relates to a pharmaceutical composition based on a chlorine dioxide solution, for use as a therapeutic agent in the topical, oral, and/or parenteral treatment of viral infections of the human or animal body, caused by SARS-CoV-2 coronaviruses.

The invention relates to a pharmaceutical composition based on a chlorine dioxide solution, for use as a therapeutic agent in the topical, oral, and/or parenteral treatment of viral infections of the human or animal body, caused by SARS-CoV-2 coronaviruses.